Germline cancer gene expression quantitative trait loci influence local and global tumor

- **mutations**
- 3 Yuxi Liu^{1,2,3}, Alexander Gusev³, Peter Kraft^{1,2,4,*}
- 1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA,
- 02115, USA
- 2. Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of
- Public Health, Boston, MA, 02115, USA
- 3. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical
- School, Boston, MA, 02215, USA
- 4. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA,
- 02115, USA
- *** Corresponding author:** Peter Kraft, PhD. Program in Genetic Epidemiology and Statistical
- Genetics, Harvard T.H. Chan School of Public Health, 655 Huntington Avenue, Boston, MA,
- 02115. Email: pkraft@hsph.harvard.edu
- **Running title:** Germline cancer gene eQTL influence tumor mutations
- **Keywords:** germline variant, somatic mutation, cancer driver gene, TMB, gene expression
- **Conflict of interest:** The authors declare no potential conflicts of interest.

Abstract

Introduction

 Cancer is a genetic disease driven by somatic events occurring in the genome over time. Identifying genes carrying driver mutations (cancer driver genes) and elucidating their roles in 42 the related signaling pathways have become primary goals in cancer genomic research because of the contribution of these genetic changes to abnormal and uncontrolled cell growth and transformation which drive the development of a malignant tumor (1-4). Many of these driver genomic alterations have been found to be clinically actionable drug or therapeutic targets for precision medicine. With the advancement of low-cost, high-throughput next-generation sequencing (NGS) technologies, genomic profiling of tumors using targeted NGS panels is becoming part of routine cancer care (5-8).

49 Different cancers are characterized by different patterns of somatic mutations (9,10). Even patients with the same cancer may have substantial heterogeneity in the overall tumor mutational burden (TMB), mutation patterns characterized by mutational signatures, or the cancer genes and oncogenic signaling pathways altered (4,11-14). These heterogeneities in the somatic mutational profile can lead to differential cancer progression, prognosis, and treatment response (15,16). A well-known example is the predictive association of TMB and response to immunotherapy (17). Mounting evidence suggests that somatic variations in tumors can have a germline genetic basis (12,18-23). This germline-somatic relationship has been established at different levels, from the impact of a single germline variant on somatic mutation rate of a cancer gene (e.g., rs25673 at 19p13.3 with *PTEN* alterations that involved in the mTOR signaling pathway) (20), to the associations between germline polygenic risk scores (PRS) and somatic mutational signatures (e.g., germline PRS of inflammatory bowel disease with APOBEC signatures in breast cancer) (23). Emerging evidence also shows an interactive effect of germline and somatic variations on

 clinical outcomes (24). However, the study of germline-somatic interactions is still at an early stage and the mechanisms responsible for these observed associations are still largely uncovered. Germline variants may affect somatic mutations through gene expression (19,22,25). In the well- established example of the APOBEC mutational process, rs17000526-A allele in the *APOBEC3B* region is associated with higher expression of this gene, which contributes to somatic mutagenesis of APOBEC signatures in bladder tumor (19). Chen et al. systematically assessed the impacts of expression level of putative cancer-susceptibility genes on mutational signatures and TMB and identified a wide range of associations across six cancer types (25). Many underlying mechanisms may co-exist, but an intuitive and interpretable hypothesis would be that the germline cancer gene expression quantitative trait loci (eQTL) alter the propensity of acquiring somatic mutations in those specific genes or globally through their regulatory effect on gene expression. Although prior studies included gene expression information in the analysis of germline-somatic interactions, this is no systematic study focusing on both the local and global impact of eQTL on somatic mutations in cancer genes across multiple cancers. Many latent associations and mechanisms may thus have been missed.

 Here, we performed a pan-cancer analysis of the germline genetic impacts on both the local and global tumor mutations, incorporating regulatory information of germline variants on gene expression. Specifically, we evaluated the associations between germline cancer gene eQTL and 80 i) somatic mutation status of those cancer genes or any hotspot mutation in those genes, ii) tumor mutation counts (TMC) of all recurrently mutated cancer genes for a cancer type, and iii) TMB of all targeted cancer genes from the OncoPanel sequencing platform across 11 cancer types in the Dana-Farber Profile cohort. Clinical targeted sequencing cohorts are well suited for such germline-somatic analysis because the tumor sequencing specifically targets those actionable

- cancer drivers and the cancer patient population is usually large, unselected, and has extensive
- clinical data. Our results demonstrate evidence for germline-somatic associations that are
- potentially mediated through cancer gene expression and provide insights into the mechanisms of
- mutagenesis in somatic cells.

Materials and Methods

Study population

 The Dana-Farber Profile, initiated in 2011, is a cohort study of unselected cancer patients who presented at the Dana-Farber Cancer Institute, Brigham and Women's Hospital, or Boston Children's Hospital, received genomic profiling and consented to participate. Tumor specimens, mainly formalin-fixed paraffin-embedded tissues, were retrieved from all consented patients for targeted sequencing. Comprehensive clinical and pathologic data were collected along with the genomic data (6,26). The study protocol was approved by the institutional review board (IRB) of Dana-Farber/Partners Cancer Care Office for the Protection of Research Subjects (11-104/17- 000). Secondary analyses of previously collected data were approved by the Dana-Farber IRB (19-033/19-025).

Tumor targeted sequencing

 A workflow of the full data generating and processing pipeline is present in **Fig. 1**. All collected tumor samples were sequenced on OncoPanel, a targeted NGS platform designed for detecting somatic variations in a panel of actionable cancer genes. There are three versions of the panel targeting the exon and/or intron regions of 304, 326, and 447 genes, respectively; each patient in the cohort was sequenced on one of the panels (Supplementary Table S1). All targeted genes were previously identified oncogenes or tumor suppressor genes involved in cancer-related 107 signaling pathways (27). Sequencing was performed using an Illumina HiSeq 2500 with 2×100 paired-end reads followed by somatic mutation calling using MuTect (for single-nucleotide variants) (28) and Indelocator (for indels; [http://www.broadinstitute.org/cancer/cga/indelocator\)](http://www.broadinstitute.org/cancer/cga/indelocator)

110 from reads aligned to the targeted genome regions with $> 50\times$ reads ("On-target reads"). More

details about the tumor sequencing pipeline can be found in prior studies (6,27).

 We collected somatic mutation data from the tumor sequences of 18,472 primary cancer samples spanning over 60 cancer types and subtypes. Some tumors exhibit microsatellite instability (MSI) with high mutational burden; the germline-somatic relationship for those hypermutable subtypes might be substantially different from the microsatellite stable (MSS) tumors. We thus 116 further classified each sample as MSI or MSS using MSIDetect (29). Cancer types with > 500 117 samples were selected; for each selected cancer, we removed those rare subtypes with $\lt 3$ samples. The remaining 12,413 samples across 11 cancer types were included in the downstream

Germline imputation from tumor sequences

analysis (Supplementary Table S2).

 Details of inferring common germline variants from the OncoPanel tumor sequencing data are described elsewhere (26) and briefly summarized here. Tumor targeted sequencing generated both high-coverage "on-target reads" aligned to the targeted regions and low-coverage "off- target reads" aligned to the rest of the genome (**Fig. 1**). Common germline variants with > 1% frequency in the European population were imputed from these tumor sequences (mainly relied on off-target reads) using linkage disequilibrium (LD) information with the 1000 Genomes Phase 3 release as the haplotype reference panel. Imputation accuracies from several algorithms designed for imputing germline variants from low coverage data were evaluated by comparing the imputed allele dosage to the gold standard germline data generated from genotyping array. The STITCH algorithm (30) yielded the highest overall accuracy and the resulting imputed germline data were used for the downstream analysis. The imputed variants were subsequently

 restricted to an imputation INFO score of greater than 0.4, which produced a mean imputation correlation of 0.86 between tumor imputed and germline SNP array variants (26).

Genetic ancestry was inferred by projecting the imputed germline genetic data into the genetic

ancestry principal components using weights derived for European, African, and Asian

populations from the 1000 Genomes Project reference data (31). We further restricted our

analysis to samples with < 10% inferred non-European ancestry.

Identifying recurrently mutated cancer genes and hotspot mutations

139 We identified recurrently mutated cancer genes, defined as genes with \geq 5% carriers of missense mutations, for each selected cancer type from the somatic data. Not all panel genes were sequenced on every sample (multiple panel versions exist); we thus further excluded those identified gene-cancer pairs with < 500 sequenced samples. We included additional genes that were identified as highly significantly mutated or significantly mutated genes among known cancer genes for each selected cancer type from the TumorPortal [\(http://www.tumorportal.org/\)](http://www.tumorportal.org/) (32). A total of 135 cancer genes and 342 gene-cancer pairs were identified, with the mutation frequency ranging from 0.0036 to 0.73 (**Fig. 2A**; Supplementary Table S3). Mutation status for each sample and gene is defined as whether this sample carries at least one functional mutation 148 (frame shift del, frame shift ins, frameshift, initiator codon, missense and splice region, 149 missense mutation, nonsense mutation, protein altering, splice site, start lost, stop lost, and translation_start_site) in this gene and is considered to capture the "local" tumor mutation (mutation in one cancer gene).

152 For each selected cancer type, we further identified specific mutations with \geq 5% carriers in the somatic data as hotspot mutations. Seven of the 11 cancer types harbor at least one hotspot

 mutation. A total of 17 hotspot mutations and 25 mutation-cancer pairs were identified, with the mutation frequency ranging from 0.051 to 0.33 (**Fig. 2B**; Supplementary Table S4). A binary variable of the local mutation status was created to indicate whether a sample carries a specific hotspot mutation.

Quantifying TMB of all panel genes and TMC of recurrently mutated cancer genes

 TMB is defined as the total number of missense mutations per megabase based on the targeted sequencing data of all panel genes (**Fig. 2C**). It captures the total mutations in all targeted cancer genes and is considered as a refined "global" mutational burden restricting to a set of cancer- related genes rather than the genome-wide mutational burden. In addition to TMB, we also calculated TMC for each sample, which is defined as the count of recurrently mutated cancer genes (specific to each cancer type) that harbor at least one missense mutation. The number of identified recurrently mutated cancer genes varies across cancer types (**Fig. 2D**). Compared to TMB, TMC is a more refined measure of the mutational burden in likely driver genes for a cancer. Moreover, by counting the genes instead of the mutations, the TMC analysis would be less sensitive to hypermutable outliers.

Identifying eQTL from the Genotype-Tissue Expression (GTEx) Project for all selected genes

 We obtained the eQTL and gene expression association results in normal tissue for all selected genes from the meta-analyzed multi-tissue eQTL results using METASOFT (33) from the GTEx Analysis V8 release. We selected those genome-wide significant eQTL with $P < 5 \times 10^{-8}$ from any of the fixed effect (FE), random effect (RE), or Han and Eskin's random effect (RE2) models. Variants with minor allele frequency < 1% were further removed. A total of 28,486

 eQTL for 114 genes with imputed germline data available were included in the analysis. We 177 performed LD clumping with $r^2 = 0.3$ on the final list of eQTL for each gene to identify independent loci, which was used to determine the number of effective tests in the association analyses (34).

Assessing the associations of cancer gene eQTL with TMB and TMC

 We assessed the association between each selected cancer gene eQTL and TMB of all panel genes for each cancer by fitting a linear model adjusting for age, gender (if applicable), panel version, and tumor purity. MSI status was also adjusted as a covariate for the models of colorectal and endometrial cancer where a substantial proportion of the cases display hypermutability (35,36). TMB was Winsorized to 98% within each cancer type to reduce the impact of potential outliers on the association results. The associations between cancer gene eQTL and TMC were evaluated for recurrently mutated cancer genes for each cancer type by fitting a negative binomial model with the same covariates as the TMB models. Sensitivity analysis was performed to assess the impacts of potential TMB or TMC outliers on the association results by varying the Winsorization thresholds and using standardized TMB. For TMC, we further evaluated the impacts of using count of missense mutations instead of count of mutated genes on the germline-somatic associations.

Assessing the associations of cancer gene eQTL with recurrently mutated cancer genes and hotspot mutations

 The local impact of each cancer gene eQTL on the risk of having somatic mutations in that gene or a nearby hotspot mutation was assessed using logistic regression. These analyses further adjusted for TMB along with all the covariates included in the TMB or TMC models. Meta-

- analysis was performed to evaluate the broad impact of a cancer gene eQTL on the mutation
- status of one gene or mutation across cancers.

Data availability statement

- The individual-level data used in this study are not publicly available due to patient privacy
- requirements. Other unidentifiable data generated in this study are available within the article
- and its supplementary data files.

Results

Germline cancer gene eQTL influence global tumor mutations

 We analyzed 28,486 eQTL for 114 cancer genes and assessed their associations with TMB of all 207 cancer genes sequenced on the panel across cancers. There were 1,317 independent eQTL (r^2 < 208 0.3) after LD clumping. We identified 22 significant eQTL-TMB associations representing 3 independent gene-cancer pairs that passed the Bonferroni correction threshold accounting for the 210 number of effective tests (P < 3.45 × 10⁻⁶; Supplementary Table S5). **Table 1** summarizes the results for the most significant association at each locus. There exists heterogeneity in the effects of these eQTL on TMB across cancers (Supplementary Table S6). Sensitivity analysis on the impacts of potential outliers showed that the association of the *GLI2* eQTL and TMB in ovarian cancer was sensitive to the changing Winsorization threshold (Supplementary Table S7). This 215 association also became non-significant if we use standardized TMB as the outcome (beta = 216 0.26, $P = 0.43$) while the other two top associations remained nominally significant (beta = -2.33 , $P = 1.57 \times 10^{-3}$ for rs139944315 (*WRN*) and TMB in glioma; beta = −0.23, $P = 0.04$ for rs11075646 (*CBFB*) and TMB in esophagogastric carcinoma).

 To further investigate the relationship between the observed germline-somatic associations and gene expression, we compared our results with the association results between the identified top eQTL and expression level of the specific cancer genes in normal tissue in GTEx (**Table 1**; **Fig. 3**). The T allele of rs1530578 was associated with elevated TMB in ovarian cancer and reduced expression of *GLI2* across tissues (**Fig. 3A,D**). The largest effect of rs1530578 on *GLI2* expression was observed in ovary with beta = -0.55 and $P = 3.93 \times 10^{-5}$ (**Fig. 3A**). rs139944315 was associated with TMB in glioma and expression of *WRN* across tissues in a consistent

 TMB in the corresponding cancers in consistent directions with TMC with nominal significance (Supplementary Table S12).

Local impacts of germline eQTL on somatic mutations in cancer genes

Investigation of the local impacts of eQTL for a cancer gene on somatic mutations in that gene is

also of interest as it may point to a direct and testable mechanism of how germline variations

271 modify the susceptibility to somatic events. None of the individual associations between somatic 272 mutation status for recurrently mutated genes and their eQTL passed the Bonferroni correction threshold $(P < 1.73 \times 10^{-5})$. The most significant association observed was between a *TSC2* 274 eQTL and somatic *TSC2* mutation status in endometrial cancer (beta = −1.81 for rs12918530-C allele, $P = 1.56 \times 10^{-4}$; Supplementary Table S13). Looking across all cancers, there was a 276 significant $(P < 6.91 \times 10^{-5})$ association between an *ATM* eQTL (lead SNP: rs4753834 at 277 11q22.3) and somatic *ATM* mutations from a meta-analysis of 8 cancers (**Fig. 5**; Supplementary 278 Table S14). The G allele of rs4753834 was associated with a lower risk of having somatic 279 mutations in *ATM* (beta = -0.35 , $P = 3.43 \times 10^{-5}$ across cancers from FE model) and increased expression of *ATM* in normal tissues (beta = 0.05 , $P = 1.03 \times 10^{-20}$ across tissues from RE 281 model). This variant also had specific effects on *ATM* expression in many tissues related the 8 282 cancers, including mammary tissue (beta $= 0.06$), sigmoid colon (beta $= 0.09$), hypothalamus 283 (beta = 0.12), lung (beta = 0.07), and prostate (beta = 0.11), all with $P < 0.05$ and m-value > 0.9 . 284 Moreover, variants that are in LD with rs4753834 have also been associated with *ATM* expression in tumor samples of breast cancer (rs673281, $r^2 = 0.21$, beta = −0.08 for the T allele, 286 $P = 1.98 \times 10^{-4}$) and glioma (rs1003623, r² = 0.21, beta = −0.11 for the T allele, $P = 4.56 \times 10^{-4}$) 287 (38); the directions were also consistent with those in normal tissues. We additionally tested the 288 associations of *ATM* eQTL and TMB or TMC of cancer genes and found that variants in LD with 289 rs4753834 (lead SNP: rs672964, $r^2 = 0.21$ with rs4753834) were associated with TMB (beta = 290 -0.69 for rs672964-C, $P = 2.97 \times 10^{-5}$) and TMC (beta = −0.07 for rs672964-C, $P = 0.02$) in 291 non-small cell lung cancer in the consistent direction with *ATM* mutation status. No association 292 with cancer risk was found for rs4753834 or its tagging SNPs in GWAS Catalog.

293 We also identified nominal associations between eQTL for cancer genes identified in the global 294 tumor mutation analysis with the somatic mutation status of that gene in the corresponding 295 cancer. We found that rs1897693 ($r^2 = 0.42$ with rs10031417) was associated with both the 296 expression of *EPHA5* in normal tissues (beta = 0.03 for the C allele, *P* = 0.03 across tissues from 297 RE model) and the somatic mutation status of *EPHA5* in colorectal cancer (beta = −0.66 for the 298 C allele, *P* = 0.01). Another variant rs55671402 was associated with *FANCA* expression in normal tissues (beta = -0.13 for the C allele, $P = 9.67 \times 10^{-13}$ across tissues from RE model; beta $= -0.54$ for the C allele, m-value = 0.98, $P = 1.35 \times 10^{-3}$ in uterus) and somatic mutations in **FANCA** in endometrial tumors (beta = -1.23 for the C allele, $P = 8.61 \times 10^{-3}$). 302 We further assessed the impacts of eQTL for a cancer gene on each identified hotspot mutation 303 in that gene. None of the associations passed the Bonferroni correction threshold ($P < 3.40 \times$ 10−4 304) with the most significant association observed for rs1867930 with p.S249C in *FGFR3* in 805 bladder cancer (beta = 0.60 for the G allele, $P = 3.54 \times 10^{-3}$; Supplementary Table S15). Only 306 one nominally significant (*P* < 0.05) association from the meta-analysis across cancers was 307 found for rs11047823 with p.G12D in *KRAS* across colorectal cancer, endometrial cancer, non-308 small cell lung cancer, and pancreatic cancer (beta $= 0.24$ for the G allele, $P = 0.01$ across 309 cancers from the FE model), though it still did not pass the Bonferroni correction threshold for 310 significance $(P < 5 \times 10^{-3})$.

Discussion

 In this study, we systematically evaluated the influence of germline variants that are associated with cancer gene expression on somatic mutations in specific cancer genes across 11 cancer types, leveraging large-scale clinical targeted panel sequencing data, germline data imputed from tumor sequences, and cancer gene eQTL data from GTEx. Our analysis revealed novel associations of germline eQTL for well-established cancer genes with local mutation status of a single cancer gene or the global mutational burden. These findings provide the initial evidence for the hypothesis that germline variants can influence local and global tumor mutations by altering the expression level of specific cancer genes. The underlying molecular mechanisms of the identified associations can be further investigated through functional analysis and in cancer cell lines.

 Although our findings are consistent with the putative mechanism that germline variants affect somatic mutations through gene expression, there are also other possible scenarios that can yield the same results (**Fig. 6**). First, given that there exists a causal impact of eQTL on somatic mutations, we still cannot conclude that this is only mediated by the transcript abundance of the specific eQTL gene. The germline eQTL may regulate the expression of other genes which contribute to somatic mutagenesis, or they might be associated with somatic mutations through other pathways that are not related to gene expression (**Fig. 6A**). Finding an eQTL signal in the cancer-related tissue can provide further support that gene expression plays a role in the germline-somatic relationship. Second, we are studying somatic mutations in developed tumor (S') rather than in normal or precancerous tissue (S) (**Fig. 6A**). S' can serve as a proxy for S, though it was measured after tumorigenesis and might be further influenced by other factors such as the tumor microenvironment (41). Here, we are studying mutations in cancer genes that have

 been identified as potential drivers for carcinogenesis. Even if some mutations in those genes occurred after cancer initiation, our results could still inform us of the role of germline variants in inducing somatic mutations during cancer progression. Finally, even when there is no direct causal effect of germline variants on somatic mutations, we may still observe this association among cancer patients. Consider the three possible scenarios in **Fig. 6B** given that a germline- somatic association was observed: germline variants may influence somatic mutation and they may or may not have an effect on cancer diagnosis through other pathways; however, under the situation that the germline variants only influence cancer diagnosis through other pathways and there is no causal effect on somatic mutations, we may still observe this germline-somatic association among cancer patients due to collider bias (**Fig. 6B**). We are unable to distinguish between these three scenarios based on our data, but we can leverage information from other sources (e.g., association results of the germline variants with cancer incidence from GWAS) to weigh these possible scenarios for each identified association.

 Most of the germline-somatic associations identified here were consistent with prior evidence, and many of them may be involved in the biological mechanisms that underlie patients' response to immunotherapy. Among all the identified eQTL genes, *APC*, *ATM*, *CBFB*, and *TP53* have been predicted as pan-cancer tumor suppressor genes across 33 cancer types in TCGA (1). We observed that the germline variants associated with reduced expression of these tumor suppressor genes were associated with increased tumor mutations, except for *APC* where the eQTL association with gene expression was close to null across tissues (but still significant) with no effect in uterus (**Table 1**; **Fig. 3-5**). The *APC* gene encodes the adenomatous polyposis coli protein which plays an important role in the Wnt signaling pathway (42) and interacts with E-cadherin, which regulates cell adhesion (43). Mutations that inactivate APC lead to disruption of

 β-catenin degradation, resulting in its translocation into the nucleus and activation of the transcription of multiple genes, which triggers cancer development, including endometrial carcinogenesis (44). Active β-catenin signaling has been linked to resistance to anti-PD-L1/anti- CTLA-4 monoclonal antibody therapy in melanoma (45). A recent study found that germline pathogenic variants in *APC* are associated with elevated TMB (46). In our work, the minor allele of the lead SNP is also associated with higher TMC of recurrently mutated cancer genes, but the direction of its association with *APC* expression is not clear (**Table 1**; **Fig. 4**). Intuitively, we would assume a variant that downregulates the expression of a tumor suppressor gene to be associated with elevated risk of cancer and somatic mutational burden, but this assumption might be oversimplified as the oncogenic or tumor suppressive effect of a gene on carcinogenesis and on somatic mutational burden would depend on the signaling pathway that the gene involved in and may vary substantially across cancer types (47). Here, the major allele of rs397768 slightly downregulates *APC* expression across tissues, if this indicates activation of β-catenin signaling in endometrial carcinogenesis, then it should be associated with resistance to immunotherapy and reduced tumor mutations as we observed. However, this interpretation depends upon many variable components involved in this complex biological process; further study is needed to elucidate the molecular mechanisms underlying these associations.

 ATM germline and somatic mutations have been linked to multiple cancers. Activated ATM protein kinase phosphorylates a few key proteins which activates DNA damage checkpoint, leading to its main tumor suppressive effect of cell-cycle arrest and apoptosis (48). A study of pathogenic germline variants in cancer identified two-hits events for *ATM* where a germline variant in *ATM* is coupled with a somatic mutation in the other copy of the gene in multiple cancers (49). They also found that *ATM* pathogenic variant carriers had lower *ATM* expression,

 which is in line with our finding that the minor allele of rs4753834 is associated with lower expression of *ATM* but higher risk of having somatic mutation in the gene (**Fig. 5**). Recent studies also reported that *ATM* mutations were associated with improved response to immune checkpoint blockade therapy (50,51). We observed this inverse relationship of *ATM* expression with both somatic *ATM* mutations across cancers and TMB in non-small cell lung cancer, which may support the potential role of *ATM* as a therapeutic target for promoting the response to cancer immunotherapy.

 TP53, which encodes protein p53, is one of the most frequently mutated genes in cancer. Genetic alterations in the p53 stress response pathway can affect the tumor suppressive role of *TP53* and promote tumorigenesis (52). Results from a recent study demonstrated evidence for the interactive effects of a germline cancer risk variant, rs78378222, and somatic mutation status of *TP53* on cancer risk, prognosis, and drug responses (24). The C allele of rs78378222 has been linked to lower expression level of wild-type *TP53* in both normal tissue and tumor, which in turns reduce p53 cellular activity and lead to poorer overall survival of patients. In our analysis, we found that the minor allele of rs17884306, which is correlated with the C allele of rs78378222, was associated with higher TMB and lower *TP53* expression (**Table 1**; **Fig. 3**). One study highlighted the predictive value of somatic *TP53* mutations for benefit from anti–PD- 1/PD-L1 immunotherapy in lung cancer (53). Our results may provide further insights into how inherited genetic predisposition can influence patients' response to immunotherapy through its effect on *TP53* expression and somatic mutational burden.

Increased expression of *GLI2* in the hedgehog signaling pathway has been found to induce PD-

- L1 expression in gastric cancer and promote tumor resistance to immunotherapy (54). We
- identified a germline eQTL at 2q14.2 that upregulates *GLI2* and is associated with lower TMB in

 ovarian cancer; nominally significant associations were also found in esophagogastric carcinoma and glioma in the same directions (**Table 1**; **Fig. 3**; Supplementary Table S6). These findings may shed light on the underlying mechanism of the link between TMB and response to immunotherapy in these specific cancers.

 Reduced *EPHA5* expression has been linked to lymph node metastasis, advanced TNM stage, and poor survival outcome in colorectal cancer, supporting its tumor suppressive role in this cancer (55). Recent work showed that having somatic *EPHA5* mutations is positively associated with TMB and response to immune checkpoint inhibitor therapy in lung cancer (56). We also identified consistent associations of an *EPHA5* eQTL at 4q13.2 with both somatic *EPHA5* mutations and the global tumor mutations in colorectal cancer. This eQTL influences *EPHA5* expression in colorectal cancer and normal colon tissue (**Table 1**; **Fig. 3**); the allele that was associated with reduced expression was also associated with increased somatic mutations. Further studies are needed to characterize the potential interactive effect of these identified germline variants, *EPHA5* expression, and somatic *EPHA5* mutations in colorectal cancer. Our study has several limitations. First, as mentioned above, we cannot easily distinguish between several possible scenarios of the causal relationships that may be consistent with the observed associations between germline eQTL and tumor mutations. We suggest future studies to further investigate these associations in normal tissue or precancerous lesions and incorporating haplotype-level information. Experimental validation is also necessary to confirm the putative mechanisms through gene expression for the identified associations. Second, the use of germline data imputed from off-target reads in tumor sequencing provides only a probabilistic estimate of the imputed variant. Although the validation analysis of imputed common germline variants against SNP array yielded high accuracy (26), it would still be important to validate

Authors' Disclosures

No disclosures were reported.

Acknowledgements

- This work was supported by National Cancer Institute grants R01CA227237 and R01CA244569
- (to A. Gusev), and R01CA260352 (to P. Kraft), Phi Beta Psi Sorority, and Emerson Collective.
- The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the
- Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA,
- NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained
- from the GTEx Portal on 08/04/2021.

References

- 52. Stracquadanio G, Wang X, Wallace MD, Grawenda AM, Zhang P, Hewitt J*, et al.* The importance of p53 pathway genetics in inherited and somatic cancer genomes. Nat Rev Cancer **2016**;16:251-65
- 53. Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY*, et al.* Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res **2017**;23:3012-24
- 54. Chakrabarti J, Holokai L, Syu L, Steele NG, Chang J, Wang J*, et al.* Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget **2018**;9:37439-57
- 55. Gu S, Feng J, Jin Q, Wang W, Zhang S. Reduced expression of EphA5 is associated with lymph node metastasis, advanced TNM stage, and poor prognosis in colorectal carcinoma. Histol Histopathol **2017**;32:491-7
- 56. Huang W, Lin A, Luo P, Liu Y, Xu W, Zhu W*, et al.* EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.
- Cancer Gene Ther **2021**;28:864-74

Table 1. Significant associations between cancer gene eQTL and global tumor mutations

^a Meta-analysis results of the associations between the eQTL and normalized gene expression levels across 49 tissues

b Position based on GRCh37/hg19

Figures

Figure 1. A workflow of the germline and somatic data generation pipeline in the Profile cohort. Tumor samples were collected from all consented patients in the Profile cohort, followed by targeted sequencing using OncoPanel. Somatic data were generated from on-target reads from the tumor sequences. Germline data were imputed using both the off-target and on-target reads generated from tumor sequencing. Four measures of the local and global tumor mutations: i) Mutation status of recurrently mutated cancer genes, ii) Mutation status of hotspot mutations, iii) TMC of recurrently mutated cancer genes, and iv) TMB of all panel genes were generated for all selected primary cancer samples across 11 cancer types from somatic data. Germline eQTL were identified from GTEx for all identified genes, followed by germline allele dosage extraction from the germline imputed data.

Figure 2. Local and global tumor mutations of 11 cancer types. A, Mutation frequency and sample size of the identified recurrently mutated cancer genes for each cancer type. A total of 135 genes were selected for 11 cancer types (Supplementary Table S3); only genes that are recurrently mutated in ≥ 5 cancer types are shown on this figure. **B,** Mutation frequency and sample size of the identified hotspot mutations for each cancer type. There are 17 hotspot mutations in 10 genes for 7 cancer types. **C,** Distribution of TMB of all panel genes across cancers with sample sizes. **D,** Distribution of TMC of recurrently mutated cancer genes across cancers. Each dot represents a sample. The red horizontal line represents the median of TMC for each cancer type. The total number of recurrently mutated cancer genes selected for each cancer is listed on the top of the figure.

Figure 3. Associations of eQTL with TMB of all panel genes and gene expression across

tissues. A-C, All selected eQTL for genes identified from the top eQTL-TMB associations are shown. Association results ($\lnot log_{10}(P)$) for eQTL and TMB are from linear models adjusting for age, gender (if applicable), tumor purity, and panel version. Association results (m-value, the posterior probability that an effect exists in a tissue) for eQTL and gene expression in the "matching tissue" are from GTEx; matching tissue was selected as the tissue with the largest mvalue among all relevant tissues for the corresponding cancer type. Each dot represents a variant; variants that are significantly associated with both TMB and gene expression (in any metaanalysis model) are in red with the top variant marked as yellow diamond. RSID, effect allele, effect size, *P* value, and m-value for the top variant are annotated on the plots. The horizontal red dashed lines denote the significant threshold for TMB associations ($P = 3.45 \times 10^{-6}$) and "has an effect" threshold for gene expression associations in the matching tissue (m-value = 0.9). **D-F,** Association results of the top variants with expression level of the eQTL genes identified from the top eQTL-TMB associations by tissue from GTEx. The −log10(*P*) are from single-tissue eQTL analysis. Each dot represents a tissue with the matching tissue for the specific cancer marked as yellow triangle. Meta-analysis results across tissues from FE and RE models are provided on the plots. See Fig. 5 for tissue annotations.

Figure 4. Associations of eQTL with TMC of recurrently mutated cancer genes and gene expression across tissues. A-F, All selected eQTL for genes identified from the top eQTL-TMC associations are shown. Association results (−log10(*P*)) for eQTL and TMC are from negative binomial models adjusting for age, gender (if applicable), tumor purity, panel version, and MSI status. Association results (m-value, the posterior probability that an effect exists in a tissue) for eQTL and gene expression in the "matching tissue" are from GTEx; matching tissue was

selected as the tissue with the largest m-value among all relevant tissues for the corresponding cancer type. Each dot represents a variant; variants that are significantly associated with both TMC and gene expression (in any meta-analysis model) are in red with the top variant marked as yellow diamond. RSID, effect allele, effect size, *P* value, and m-value for the top variants are annotated on the plots. The horizontal red dashed lines denote the significant threshold for TMC associations ($P = 1.73 \times 10^{-5}$) and "has an effect" threshold for gene expression associations in the matching tissue (m-value $= 0.9$). **G-L,** Association results of the top variants with the expression level of the eQTL genes identified from the top eQTL-TMC associations by tissue from GTEx. The −log10(*P*) are from single-tissue eQTL analysis. Each dot represents a tissue with the matching tissue for the specific cancer marked as yellow triangle. Meta-analysis results across tissues from FE and RE models are provided on the plots. See Fig. 5 for tissue annotations.

Figure 5. rs4753834 is associated with both *ATM* **expression and somatic** *ATM* **mutations.**

A, Associations between rs4753834 and risk of having somatic mutations in *ATM* across 8 cancers. The odds ratio is associated with the G allele of rs4753834. Meta-analysis results from the fixed-effect model are shown. **B,** Sample sizes and mutation frequencies of the 8 cancer types. Note that these numbers are based on samples included in the final models. **C,** Association results of rs4753834 and *ATM* expression by tissue from GTEx. The −log₁₀(*P*) are from singletissue eQTL analysis. m-value is the posterior probability that an effect exists in a tissue. Results from the FE and RE meta-analysis across tissues are also shown on the plot.

Figure 6. Hypothetical relationships between germline variants, cancer gene expression, somatic mutations, and cancer diagnosis. A, Complete relationships between germline eQTL, environmental factors (E), expression level of cancer genes in normal tissue (transcript

abundance, T), somatic mutations in cancer genes in normal tissue before tumor development (S), cancer diagnosis (D), and somatic mutations in cancer genes in tumor after cancer diagnosis (S'). Our hypothesis is that germline eQTL regulate the expression of cancer genes; the transcript abundance of those cancer genes modifies the propensity of acquiring somatic mutations in those genes; having somatic mutations in those cancer genes is associated with an increased risk of cancer (the path shown by red arrows). Here, we are testing the associations between the eQTL and S', which can serve as a proxy for S, among cancer patients (conditioning on D). **B,** Three possible relationships between germline variants (G), somatic mutations in normal tissue before tumor development (S), cancer diagnosis (D), and somatic mutations in tumor after cancer diagnosis (S') given that an association between G and S' is observed. Blue arrows on the graphs show the paths from G to S' through S given that only cancer patients are included in the study (conditioning on D).

 $\text{eQTL} \rightarrow \text{T} \rightarrow \text{S}$ **D E A S' T**

G induces S G induces S and cancer

No effect of G on S